A lot of patients are being treated inappropriately with the wrong therapies because they're either under-diagnosed or over-diagnosed.

It's like playing Battleship with the prostate. Every hole that we have has a coordinate, and we can place the needle through that. We have a picture that overlays and shows us the prostate and where that biopsy's being taken from. Then, we can basically look at the picture when we get a positive biopsy back and see exactly where the cancer is in the gland.

Unfortunately, we're finding that [the TRUS biopsy] is really not very effective at all. When you look at the statistics of a normal size gland the chances of actually finding that tumor are about 15 percent. So, 85 percent of patients by that biopsy method may be missing their cancer.

We find that a lot of them have very significant cancer that needs to be treated but wouldn't have been treated unless we had done this biopsy.

It is completely unacceptable how patients are treated by some of the staff and something has to be done.

The new treatments are smart therapies, as they go after the stimulus in the back of the eye that's causing the blood vessels to grow. By attacking the stimulus, it stops the blood vessels from leaking, it stops the blood vessels from growing, and in some cases, it actually causes the blood vessels to regress.